Antiandrogens Market Size was valued at USD 5.19 Billion in 2022. The Antiandrogens market industry is projected to grow from USD 5.4 Billion in 2023 to USD 9.5 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.1% during the forecast period (2023 - 2032).The growing incidence of prostate cancer and the increased research and development efforts are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Market CAGR for antiandrogens is being driven by the rising number of cancer patients. According to GLOBOCAN data, 1,414,259 instances of prostate cancer, or 7.3% of all cancer cases globally, were reported in 2020. Because there is such a high incidence of prostate cancer worldwide, there is a high need for effective treatments, which fuels the market for androgen deprivation therapy. Prostate cancer is widespread among adults 65 and older, according to a report released by the American Cancer Society in January 2022. The market will thus be driven by the expanding elderly population, which will also increase demand for its therapies. In 2050, 15 billion people worldwide, up from 727 million today, will be over 65, according to World Population Prospects' estimates for 2020. Thus, an aging population is anticipated to fuel market expansion. Additionally, market expansion will be aided by major market participants' methods, including collaborations, distribution contracts, mergers, and acquisitions.
The prevalence of prostate cancer in men, androgenic alopecia (male pattern hair loss), benign prostatic hyperplasia, premature puberty in young guys, and hypersexuality are expected to rise throughout the forecast period, driving demand for antiandrogens. Additionally, the market for antiandrogens is anticipated to be driven by the growth in acne, amenorrhea (the absence of monthly cycles), hirsutism (excessive face or body hair), and polycystic ovarian syndrome in women. In the United States, there are 5.7 million individuals who suffer from hypersexuality condition, according to Sexual Health Matters. Over 95% of men in the United States experience hair loss each year, according to the American Hair Loss Association, which attributes this to androgenic alopecia, also known as common male pattern baldness. Anti-androgens are medications that attach to androgen receptors and prevent androgens from promoting the formation of tumors. Androgen receptor antagonists are another name for anti-androgens. Flutamide (Eulexin), Bicalutamide (Casodex), Enzalutamide (Xtandi), Apalutamide (Erleada), and Darolutamide (Nubeqa) are antiandrogen medications.Prostate cancer occurrences are increasing worldwide, and factors like product approvals, an aging population, increased R&D efforts, and strategies used by major market players, including collaborations, will all significantly boost market growth.Thus, driving the Antiandrogens market revenue.
Based on type, the Antiandrogens market segmentation includes steroidal and nonsteroidal. The nonsteroidal segment dominated the market, accounting for 65% of market revenue. Anti-androgens are medications that attach to androgen receptors and prevent androgens from promoting the formation of tumors. Androgen receptor antagonists are another name for anti-androgens. Flutamide (Eulexin), Bicalutamide (Casodex), Enzalutamide (Xtandi), Apalutamide (Erleada), and Darolutamide (Nubeqa) are antiandrogen medications. Prostate cancer occurrences are increasing worldwide, and factors like product approvals, an aging population, increased R&D efforts, and strategies used by major market players, including collaborations, will all significantly boost market growth.
Based on disease indication, the Antiandrogens market segmentation includes prostate cancer, benign prostatic hyperplasia, hirsutism, hyperandrogenism, and others. The prostate cancer segment dominated the market, accounting for 65% of market revenue. The older population has increased due to lower morbidity rates in affluent nations, making them more vulnerable to prostate cancer. Therefore, the prevalence of prostate cancer is influenced by a rise in the elderly population, sedentary lifestyles in affluent nations, and childhood obesity. As a result, there is a greater need and higher demand for prostate cancer therapies. The National Library of Medicine reports that in 2022, cancer will be responsible for 2,68 490 new cases and 34,500 fatalities (3.8% of all cancer-related deaths in males). The average age at diagnosis is 66 years, and both the incidence and death rate of prostate cancer rises with age globally.
Based on distribution channels, the Antiandrogens market segmentation includes hospital, retail, and online pharmacies. Online pharmacies category generated the most income. Patients can buy antiandrogens in a simple method through online pharmacies. Patients may order antiandrogens from the convenience of their homes, and the medications can be delivered right to their front door. Compared to hospital and retail pharmacies, online pharmacies frequently have lower costs for antiandrogens. This is because compared to conventional brick-and-mortar pharmacies, internet pharmacies do not have the same overhead expenses.
Figure 1: Antiandrogens Market, by Distribution channel, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Antiandrogens market area will dominate this market, Prostate cancer, a serious problem in North America, is frequently treated with antiandrogens. The use of targeted medicines and combination therapy, among other recent advancements in cancer treatment, may have affected the market's expansion.
Further, the major countries studied in the market report are The US, Canada, German, France, Italy, Spain, UK, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: ANTIANDROGENS MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe has the second-largest market share for Antiandrogens. As the population of Europe ages, so does vulnerability to diseases like prostate cancer, for which antiandrogens are an important therapy option. The prevalence of prostate cancer is increasing across the continent, which has increased demand for antiandrogens and led to market growth. Furthermore, the German Antiandrogens market dominated, while the UK Antiandrogens market grew fastest in Europe.
From 2023 to 2032, the Asia-Pacific Antiandrogens Market will develop the quickest CAGR Applications of Antiandrogens. Advanced antiandrogen drugs have been introduced due to expanding medical research and development spending and bettering healthcare infrastructure. The creation of targeted medicines, combination treatments, and improved drug delivery techniques has been made possible through cooperative efforts between pharmaceutical corporations, research institutes, and healthcare practitioners. These developments improve patient outcomes and help the antiandrogens industry grow. Furthermore, China's Antiandrogens market had the highest market share. In contrast, the Asia-Pacific region's Antiandrogens market in India was the one that was growing the quickest.
Antiandrogens Key Market Players & Competitive Insights
Leading market companies are extensively spending R&D on increasing their product lines, which will help the Antiandrogens market grow even more. Important market developments include contractual agreements, new product releases, acquisitions and mergers, greater investments, and collaboration with other organizations. The Antiandrogens must produce cost-effective merchandise to flourish and thrive in a more competitive and increasing market climate.
Manufacturing locally to reduce operating costs is an effective business strategy manufacturers use in the worldwide Antiandrogens to serve clients and expand the market sector. The Antiandrogens has provided some of the most important benefits recently. AstraZeneca Plc, and other major competitors in the Antiandrogens market are seeking to improve market demand by investing in R&D efforts.
AstraZeneca Plc is a pharmaceutical firm focusing on patients, guided by science. AstraZeneca Plc is committed to revolutionizing future healthcare by utilizing science's potential to benefit individuals, society, and the environment. AstraZeneca Plc is committed to providing a fantastic workplace. One where each person who chooses to work at our organization has the opportunity to benefit patients, society, and the environment positively. AstraZeneca Plc works to create a culture where everyone feels like they belong and is free to fulfill their potential, give their all, and contribute positively to the business.
Genentech's biotechnology business is committed to conducting ground-breaking research to find and provide treatments for patients with serious and life-threatening illnesses. The first targeted antibody for cancer and the first treatment for primary progressive multiple sclerosis are only two examples of their game-changing breakthroughs. They are proud of their distinguished past as the forerunners of scientific discoveries with a remarkable track record of enhancing people's lives. Nevertheless, their goals are higher and more audacious. They have joined forces in a daring effort to address the most difficult health issues facing humanity while benefiting society. Dependent upon everyone who works here having a pleasant experience, being engaged, and being resilient, they can provide patients with transforming medications. Their employees are the core of Genentech and the energy behind the advancement that provides vital new medications to those in need.
Key Companies in the Antiandrogens market include
Pfizer Inc.
Astellas Pharma Inc.
F. Hoffmann-La Roche Ltd.
AstraZeneca Plc
Abbott Laboratories
Takeda Pharmaceutical Company Limited
OSI Pharmaceuticals, Inc.
Genentech Inc.
Bristol-Myers Squibb Company
Novartis AG
Progenics Pharmaceuticals, Inc.,
ALZA Corporation
Sanofi SA
GlaxoSmithKline Plc
Amgen Inc
ANI Pharmaceuticals, Inc.
Others.
Antiandrogens Industry Developments
May 2023:Recent research has confirmed the harmful effects of second-generation antiandrogens on cognition and functioning processes. Thirteen,524 men with metastatic or nonmetastatic prostate cancer treated or not with abiraterone, darolutamide, apalutamide, or enzalutamide were included in 12 randomized clinical studies published between 2011 and 2020. Kevin T. Nead, MPhil, MD, MD Anderson Cancer Centre, University of Texas in Houston, and colleagues reported in JAMA Oncology that second-generation antiandrogen users had a substantially 2.1-fold greater risk of cognitive adverse effects than nonusers.
Steroidal
Nonsteroidal
Prostate Cancer
Benign Prostatic Hyperplasia
Hirsutism
Hyperandrogenism
Others
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Australia
Rest of Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 5.19 Billion |
| Market Size 2023 | USD 5.4 Billion |
| Market Size 2032 | USD 9.5 Billion |
| Compound Annual Growth Rate (CAGR) | 7.1% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Diseases Indication, Distribution Channel, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Pfizer Inc., Astellas Pharma Inc., F. Hoffmann-La Roche Ltd., AstraZeneca Plc, Abbott Laboratories, Takeda Pharmaceutical Company Limited, OSI Pharmaceuticals, Inc., Genentech Inc., Bristol-Myers Squibb Company, Novartis AG, Progenics Pharmaceuticals, Inc., ALZA Corporation, Sanofi SA, GlaxoSmithKline Plc, Amgen Inc, ANI Pharmaceuticals, Inc., and others. |
| Key Market Opportunities | Advancement in medicine |
| Key Market Dynamics | Increase in cancer |
Antiandrogens Market Highlights:
Frequently Asked Questions (FAQ) :
The global Antiandrogens market size was valued at USD 5.19 Billion in 2022.
The global market is projected to grow at a CAGR of 7.1% during the forecast period, 2023-2032.
North America had the largest share in the global market
The key players in the market are Pfizer Inc., Astellas Pharma Inc., F. Hoffmann-La Roche Ltd., AstraZeneca Plc, Abbott Laboratories, Takeda Pharmaceutical Company Limited.
The Nonsteroidal dominated the market in 2022.
The Online Pharmacies had the largest share in the global market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
